Prevention of Chest Pain in Chemo-treated Cancer Patients (CATCH)

Vejle Hospital

Status: Completed

Conditions: 5-Fluorouracil Toxicity; Cardiotoxicity; Acute Coronary Syndrome; Solid Carcinoma; Chemotherapeutic Toxicity; Chest Pain; Coronary Artery Calcification

Treatments: Procedure: Cardiologic assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT03486340

CATCH2018

Details and patient eligibility

About

This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment prior to the 5-FU treatment. The investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic patients will reduce the number of hospitalisations and investigations for acute coronary syndrome during and after 5-FU treatment and that patients with high coronary artery calcium scores are more likely to experience chest pain during the treatment with 5-FU.

Enrollment: 218 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically verified cancer
• First-time treatment with 5-FU/Capecitabine
• Expected remaining lifetime > 6 months
• Informed consent

Exclusion criteria

• Known ischemic heart disease
• Ischemia-suspicious symptoms prior to 5-FU treatment
• Ischemia-suspicious ECG-changes prior to 5-FU treatment

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

218 participants in 2 patient groups

Cardiological assessment

Experimental group

Description:

a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment

Treatment:

Procedure: Cardiologic assessment

Standard treatment

No Intervention group

Description:

Standard chemotherapeutic treatment